<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04165161</url>
  </required_header>
  <id_info>
    <org_study_id>2018_0098</org_study_id>
    <nct_id>NCT04165161</nct_id>
  </id_info>
  <brief_title>Performance Diagnosis of a Patent Foramen Ovale During Lung Transplantation Using Transesophageal Echocardiography</brief_title>
  <acronym>FOP-TP</acronym>
  <official_title>Performance Diagnosis of a Patent Foramen Ovale During Lung Transplantation Using Transesophageal Echocardiography: Comparison of the Injection of Contrast in the Upper and Lower Caval Territories (FOP-TP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital Foch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hopital Foch</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesis is that an injection into the inferior vena cava associated with
      a provocation maneuver should allow to increase the incidence of FOP found by transesophageal
      echocardiography in a population of patients undergoing lung transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 30, 2019</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>For each patient the 4 tests will be performed in a randomized order to limit bias</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of transatrial passage of contrast media</measure>
    <time_frame>1 day after lung transplantation</time_frame>
    <description>Incidence of transatrial passage of contrast media</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Size of PFO, existence of an atrial septal aneurysm</measure>
    <time_frame>1 day after lung transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of postoperative days with mechanical ventilation</measure>
    <time_frame>30 days after lung transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of pulmonary graft dysfunction, incidence of stroke, incidence of myocardial ischemia</measure>
    <time_frame>30 days after lung transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality during the stay in the intensive care unit</measure>
    <time_frame>30 days after lung transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality during the stay in the hospital</measure>
    <time_frame>30 days after lung transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality at the postoperative 30-day</measure>
    <time_frame>30 days after lung transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Lung Transplant; Complications</condition>
  <arm_group>
    <arm_group_label>superior without positive tele-expiratory pressure</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Diagnostic Test: Contrast injection in the superior vena cava territory + controlled ventilation without positive tele-expiratory pressure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>superior with 10 cmH2O positive tele-expiratory pressure</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Diagnostic Test: Contrast injection in the superior vena cava territory + controlled ventilation with 10 cmH2O positive tele-expiratory pressure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>inferior without positive tele-expiratory pressure</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Diagnostic Test: Contrast injection in the inferior vena cava territory + controlled ventilation without positive tele-expiratory pressure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>inferior with 10 cmH2O positive tele-expiratory pressur</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Diagnostic Test: Contrast injection in the inferior vena cava territory + controlled ventilation with 10 cmH2O positive tele-expiratory pressure</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>search for a patent foramen ovale</intervention_name>
    <description>Injection of a contrast solution A - In the upper cellar territory with controlled ventilation without positive tele-expiratory pressure; B - In the upper cellar territory in controlled ventilation with a positive end-to-expiratory pressure of 10cm H2O; C - In the lower cellar territory with controlled ventilation without positive tele-expiratory pressure; D - In the lower cellar territory in controlled ventilation with a positive end-to-expiratory pressure of 10cm H2O;</description>
    <arm_group_label>inferior with 10 cmH2O positive tele-expiratory pressur</arm_group_label>
    <arm_group_label>inferior without positive tele-expiratory pressure</arm_group_label>
    <arm_group_label>superior with 10 cmH2O positive tele-expiratory pressure</arm_group_label>
    <arm_group_label>superior without positive tele-expiratory pressure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 years old minimum

          -  Benefiting from a lung transplant

          -  Having an upper vena cava catheter and a lower vena cava catheter set up as part of
             the usual care

          -  Having signed a consent form

          -  Affiliated to a insurance scheme or beneficiary (excluding AME)

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Having a contraindication to the insertion of the esophageal ultrasound probe

          -  Having a FOP already recognized before the intervention

          -  deprived of liberty or under guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Béatrice Angemont, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Foch</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc Fischler, MD, PhD</last_name>
    <phone>+33(0)146252442</phone>
    <email>m.fischler@hopital-foch.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elisabeth Hulier-Ammar</last_name>
    <phone>+33 1 46 25 11 75</phone>
    <email>drci-promotion@hopital-foch.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Béatrice Angemont, MD</last_name>
      <email>b.angemont@hopital-foch.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 29, 2019</study_first_submitted>
  <study_first_submitted_qc>November 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2019</study_first_posted>
  <last_update_submitted>November 13, 2019</last_update_submitted>
  <last_update_submitted_qc>November 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Foramen Ovale, Patent</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

